BMO Capital Starts Ra Pharma (RARX) at Outperform

Go back to BMO Capital Starts Ra Pharma (RARX) at Outperform

Credit Suisse Starts Ra Pharma (RARX) at Outperform

November 21, 2016 6:57 AM UTC

Credit Suisse initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $19.00.

Analyst Kennen MacKay commented, "We view RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria (PNH) with potential to capture >30% market... More

Jefferies Starts Ra Pharma (RARX) at Buy

November 21, 2016 6:51 AM UTC

Jefferies initiates coverage on Ra Pharma (NASDAQ: RARX) with a Buy rating and a price target of $25.00.

Analyst Eun Yang commented, "Utilizing its peptide chemistry platform, RARX focus on complement-mediated diseases. Given well-validated C5 target & encouraging Ph1 data, we view lead candidate... More